TP53 and coronary artery disorder: Ample evidence supports the causal relationship of reduced levels of Sirt1 expressions and atherosclerosis by reporting downregulation of Sirt1 in monocytes (Breitenstein et al., 2013[6]; Chan et al., 2017[8]) and in atherosclerotic areas (Thompson et al., 2014[35]) in CAD patients and the effects of Sirt1 in preventing the formation of foam cells in endothelial cells (Stein and Matter, 2011[31]), but simultaneous determination of Sirt1 and p53 levels in epicardial adipose tissue has not been investigated so far in coronary artery diseases.